ClinConnect ClinConnect Logo
Search / Trial NCT06971627

Telehealth Monitoring in Inflammatory Bowel Disease: Effects on Medication Compliance, Self-Efficacy, and Quality of Life

Launched by ISTANBUL UNIVERSITY - CERRAHPASA · May 7, 2025

Trial Information

Current as of June 06, 2025

Recruiting

Keywords

Inflammatory Bowel Disease Medication Compliance Self Efficacy Quality Of Life Telehealth Monitoring Crohn&Amp;#39;S Disease Ulcerative Colitis

ClinConnect Summary

This clinical trial is looking at how a special program using telehealth—where patients receive care and support remotely—can help people with inflammatory bowel disease (IBD) stick to their medication, feel more confident in managing their health, and improve their overall quality of life. Participants will be randomly assigned to either a group that receives a structured telehealth program led by nurses for three months, which includes education, counseling, and regular check-ins, or to a control group that will only receive standard care and an educational booklet.

To join the study, participants should be at least 18 years old, have been diagnosed with IBD for at least six months, and be in a stable condition. They should also be able to read and write in Turkish and use a smartphone for video calls and messaging. The trial is currently recruiting participants, and those who take part will be evaluated before starting the program and again after 12 weeks to see how well the telehealth support worked.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Individuals aged 18 years or older
  • Individuals aged 18 years or older
  • Able to read and write in Turkish
  • Diagnosed with inflammatory bowel disease (IBD) for at least 6 months
  • In clinical remission (Harvey-Bradshaw Index score \< 5 or Simple Clinical Colitis Activity Index score \< 3)
  • Able to use a smartphone
  • Have access to an online messaging application (e.g., WhatsApp) and a valid e-mail address
  • Capable of downloading and using a mobile or computer-based video conferencing application (e.g., Zoom)
  • Willing to participate in the study voluntarily
  • Exclusion Criteria:
  • Diagnosed with any psychiatric or cognitive disorder
  • Having any condition that impairs communication
  • Pregnant women
  • Patients receiving infusion-based treatment
  • Having an advanced chronic disease

About Istanbul University Cerrahpasa

Istanbul University - Cerrahpasa is a prestigious academic institution renowned for its commitment to advancing medical research and education. With a focus on innovative clinical trials, the university harnesses cutting-edge methodologies to address pressing health challenges. Its collaborative environment fosters interdisciplinary research, enabling the development of effective therapeutic strategies and enhancing patient care. The institution's dedication to ethical standards and patient safety underscores its reputation as a leader in clinical research within the region and beyond.

Locations

Istanbul, , Turkey

Patients applied

0 patients applied

Trial Officials

Kimya Kılıçaslan, PhD Candidate

Principal Investigator

Istanbul University - Cerrahpasa Institute of Graudate Studies

Zeliha Tulek, PhD, Prof.

Study Director

Istanbul University - Cerrahpasa, Florence Nightingale Faculty of Nursing

Aykut Ferhat Çelik, MD, Prof.

Study Chair

Istanbul University - Cerrahpasa Cerrahpaşa Faculty of Medicine Department of Gastroenterology

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported